NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
Clinical Trials
12 trialsNCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT05012644 2024-10-08
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
Pfizer
Completed
NCT05361655 2024-06-07
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
Pfizer
Completed
NCT05043506 2024-03-27
EUCHARIS
Pfizer
Completed
NCT03462251 2023-01-19
RIBBIT
iOMEDICO AG
Phase 3 Completed
NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01491737 2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2 Completed
NCT01446159 2020-06-02
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
MedImmune LLC
Phase 2 Completed
NCT02970682 2019-07-12
STEM
Evgen Pharma
Phase 2 Completed
NCT00044291 2015-07-31
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Completed
NCT00784888 2012-03-15
TAMARA
Pfizer
Completed